A61K 31/502
Ortho- or peri-condensed with carbocyclic ring systems
Official title: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K31/502 (Ortho- or peri-condensed with carbocyclic ring systems) appears on 604 US grants and 1,308 published applications in this corpus.
Search patents in A61K- Granted patents
- 604
- Published applications
- 1,308
- Assignees
- 648
- Inventors
- 3,069
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 3 | 0 |
| 2000 | 8 | 0 |
| 2001 | 11 | 0 |
| 2002 | 10 | 13 |
| 2003 | 5 | 21 |
| 2004 | 10 | 27 |
| 2005 | 9 | 20 |
| 2006 | 5 | 23 |
| 2007 | 5 | 20 |
| 2008 | 4 | 21 |
| 2009 | 5 | 23 |
| 2010 | 8 | 29 |
| 2011 | 11 | 25 |
| 2012 | 12 | 24 |
| 2013 | 24 | 46 |
| 2014 | 33 | 56 |
| 2015 | 36 | 42 |
| 2016 | 35 | 55 |
| 2017 | 36 | 47 |
| 2018 | 25 | 47 |
| 2019 | 28 | 63 |
| 2020 | 29 | 83 |
| 2021 | 36 | 90 |
| 2022 | 41 | 90 |
| 2023 | 35 | 110 |
| 2024 | 48 | 118 |
| 2025 | 50 | 121 |
| 2026 | 35 | 94 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- HER3 radioimmunotherapy for the treatment of solid cancers1 Sep 2026US 12,721,915 B2Actinium Pharmaceuticals, Inc.
- Bacterial DNA gyrase inhibitors and methods of use thereof25 Aug 2026US 12,714,692 B2The Florida International University Board of Trustees
- Compositions having improved bioavailability of therapeutics14 Jul 2026US 12,678,502 B2TRx Biosciences Limited
- Combination therapy of tetracyclic quinolone analogs for treating cancer7 Jul 2026US 12,673,062 B2Senhwa Biosciences, Inc.
- Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations7 Jul 2026US 12,673,961 B2Agios Pharmaceuticals, Inc.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Combination therapy of tetracyclic quinolone analogs for treating cancer1 Oct 2026US 2026/0294930 A1Senhwa Biosciences, Inc.
- Substituted acetylene compound derivatives and their pharmaceutical use1 Oct 2026US 2026/0297083 A1Avelos Therapeutics Inc.
- Il-15 inhibitors useful for the treatment of atopic dermatitis1 Oct 2026US 2026/0297174 A1Novartis Pharma AG
- Combination therapies for homologous recombination deficient cancers24 Sep 2026US 2026/0284045 A1
Most cited
By later US patents
- Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction140US 6,037,346 AVivus, Inc. · 2000
- FLK-1 is a receptor for vascular endothelial growth factor90US 5,851,999 AMax-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V. · 1998
- Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction85US 6,127,363 AVivus, Inc. · 2000
- Quinazoline compounds and compositions thereof for the treatment of disease84US 5,792,771 ASugen, Inc. · 1998
- Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation68US 6,403,597 B1Vivus, Inc. · 2002